New drug duo aims to stop smoldering myeloma from becoming full-blown cancer
NCT ID NCT02960555
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug isatuximab, given alone or with lenalidomide, can control or shrink the signs of smoldering multiple myeloma in people at high risk of developing active disease. About 61 participants receive the treatment to see if it delays progression and improves outcomes. The goal is to manage the condition and prevent it from worsening.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING PLASMA CELL MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common arthritis drug hold off a rare blood cancer?
- Can keytruda stop smoldering myeloma in its tracks?
- Could a common arthritis drug slow down multiple myeloma?
- Simple lifestyle changes and a common heart drug may improve quality of life for myeloma patients
- New study asks: how do early blood disorders really affect daily life?
- Could a drug combo stop smoldering myeloma in its tracks?